Duyster J - Search Results

1

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).

Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N. Jilg S, et al. Among authors: duyster j. Int J Cancer. 2019 Oct 15;145(8):2292-2303. doi: 10.1002/ijc.32282. Epub 2019 Apr 29. Int J Cancer. 2019. PMID: 30882891 Free article. Clinical Trial.

2

Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Bai RY, et al. Among authors: duyster j. Blood. 2000 Dec 15;96(13):4319-27. Blood. 2000. PMID: 11110708 Free article.

3

Grb4/Nckbeta acts as a nuclear repressor of v-Abl-induced transcription from c-jun/c-fos promoter elements.

Jahn T, Seipel P, Coutinho S, Miething C, Peschel C, Duyster J. Jahn T, et al. Among authors: duyster j. J Biol Chem. 2001 Nov 16;276(46):43419-27. doi: 10.1074/jbc.M107030200. Epub 2001 Aug 20. J Biol Chem. 2001. PMID: 11514578 Free article.

4

Role for the adaptor protein Grb10 in the activation of Akt.

Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Jahn T, et al. Among authors: duyster j. Mol Cell Biol. 2002 Feb;22(4):979-91. doi: 10.1128/MCB.22.4.979-991.2002. Mol Cell Biol. 2002. PMID: 11809791 Free PMC article.

5

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

von Bubnoff N, Schneller F, Peschel C, Duyster J. von Bubnoff N, et al. Among authors: duyster j. Lancet. 2002 Feb 9;359(9305):487-91. doi: 10.1016/S0140-6736(02)07679-1. Lancet. 2002. PMID: 11853795

6

Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors.

Keller U, Götze KS, Duyster J, Schmidt B, Rose-John S, Peschel C. Keller U, et al. Among authors: duyster j. Leukemia. 2002 Oct;16(10):2122-8. doi: 10.1038/sj.leu.2402660. Leukemia. 2002. PMID: 12357366

7

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Grundler R, et al. Among authors: duyster j. Blood. 2003 Jul 15;102(2):646-51. doi: 10.1182/blood-2002-11-3441. Epub 2003 Mar 27. Blood. 2003. PMID: 12663439 Free article.

8

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.

von Bubnoff N, Peschel C, Duyster J. von Bubnoff N, et al. Among authors: duyster j. Leukemia. 2003 May;17(5):829-38. doi: 10.1038/sj.leu.2402889. Leukemia. 2003. PMID: 12750693 Review.

9

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.

Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J. Miething C, et al. Among authors: duyster j. Leukemia. 2003 Sep;17(9):1695-9. doi: 10.1038/sj.leu.2403040. Leukemia. 2003. PMID: 12970766

10

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.

von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. von Bubnoff N, et al. Among authors: duyster j. Cancer Res. 2003 Oct 1;63(19):6395-404. Cancer Res. 2003. PMID: 14559829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page